Monensin was further shown to act synergistically with EGFR inhibitors and the chemotherapeutic drug oxaliplatin to inhibit cell proliferation and induce apoptosis of human ovarian cancer cells. The gene discussed is EGFR; the disease is ovarian carcinoma.